Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial.

Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis GN, Efstathiadou Z, Kita M, Avramidis A

International journal of clinical practice17 Apr 2008Cited by 25 (Europe PMC)

PMID18422590DOI10.1111/j.1742-1241.2008.01768.xPepBankPUB-18422590

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with postmenopausal osteoporosis, lumbar spine BMD increases did not differ significantly between teriparatide and risedronate.
In plain wordsSpine bone density increases did not differ significantly between teriparatide and risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeLumbar spine BMD versus risedronate
Study
n = 44
Comparator
Risedronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg once daily · 12 monthsAs given in this study (human).
Source sentences
Summary
Finally, lumbar spine BMD increased significantly in both RIS (p = 0.003) and TPTD groups (p < 0.001) without significant differences between them.
1 context sentence(design, population, supporting numbers)
Summary · context
Forty-four Caucasian women (age 65.1 +/- 1.6 years) with postmenopausal osteoporosis were randomly assigned to receive either RIS 35 mg once weekly (n = 22) or TPTD 20 microg once daily (n = 22) for 12 months.
Report a problemFND-1842259006
02HumanRandomized controlled trialEfficacy outcome
In women with postmenopausal osteoporosis, P1NP increased during teriparatide treatment compared with baseline.
In plain wordsTeriparatide increased P1NP compared with baseline in women with osteoporosis.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseP1NP
Study
n = 22
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg once daily · 12 monthsAs given in this study (human).
Source sentences
Summary
P1NP, CTx and total ALP levels decreased in RIS group (p < 0.001) and increased in TPTD group (p < 0.001) throughout the treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Forty-four Caucasian women (age 65.1 +/- 1.6 years) with postmenopausal osteoporosis were randomly assigned to receive either RIS 35 mg once weekly (n = 22) or TPTD 20 microg once daily (n = 22) for 12 months.
Report a problemFND-1842259001
03HumanRandomized controlled trialEfficacy outcome
In women with postmenopausal osteoporosis, CTx increased during teriparatide treatment compared with baseline.
In plain wordsTeriparatide increased CTx compared with baseline in women with osteoporosis.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCTx
Study
n = 22
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg once daily · 12 monthsAs given in this study (human).
Source sentences
Summary
P1NP, CTx and total ALP levels decreased in RIS group (p < 0.001) and increased in TPTD group (p < 0.001) throughout the treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Forty-four Caucasian women (age 65.1 +/- 1.6 years) with postmenopausal osteoporosis were randomly assigned to receive either RIS 35 mg once weekly (n = 22) or TPTD 20 microg once daily (n = 22) for 12 months.
Report a problemFND-1842259002
04HumanRandomized controlled trialEfficacy outcome
In women with postmenopausal osteoporosis, total ALP increased during teriparatide treatment compared with baseline.
In plain wordsTeriparatide increased total alkaline phosphatase compared with baseline in women with osteoporosis.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal ALP
Study
n = 22
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg once daily · 12 monthsAs given in this study (human).
Source sentences
Summary
P1NP, CTx and total ALP levels decreased in RIS group (p < 0.001) and increased in TPTD group (p < 0.001) throughout the treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Forty-four Caucasian women (age 65.1 +/- 1.6 years) with postmenopausal osteoporosis were randomly assigned to receive either RIS 35 mg once weekly (n = 22) or TPTD 20 microg once daily (n = 22) for 12 months.
Report a problemFND-1842259003
05HumanRandomized controlled trialEfficacy outcome
In women with postmenopausal osteoporosis, iPTH decreased during teriparatide treatment compared with baseline.
In plain wordsTeriparatide decreased intact parathyroid hormone compared with baseline in women with osteoporosis.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseIntact parathyroid hormone
Study
n = 22
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg once daily · 12 monthsAs given in this study (human).
Source sentences
Summary
iPTH increased significantly in RIS group (p < 0.05) and decreased in TPTD group (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Forty-four Caucasian women (age 65.1 +/- 1.6 years) with postmenopausal osteoporosis were randomly assigned to receive either RIS 35 mg once weekly (n = 22) or TPTD 20 microg once daily (n = 22) for 12 months.
Report a problemFND-1842259004
06HumanRandomized controlled trialEfficacy outcome
In women with postmenopausal osteoporosis, lumbar spine BMD increased significantly with teriparatide compared with baseline.
In plain wordsTeriparatide increased spine bone density compared with baseline in women with osteoporosis.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD change
Study
n = 22
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg once daily · 12 monthsAs given in this study (human).
Source sentences
Summary
Finally, lumbar spine BMD increased significantly in both RIS (p = 0.003) and TPTD groups (p < 0.001) without significant differences between them.
1 context sentence(design, population, supporting numbers)
Summary · context
Forty-four Caucasian women (age 65.1 +/- 1.6 years) with postmenopausal osteoporosis were randomly assigned to receive either RIS 35 mg once weekly (n = 22) or TPTD 20 microg once daily (n = 22) for 12 months.
Report a problemFND-1842259005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT00853723

Comparison Study of PTHrP and PTH to Treat Osteoporosis

University of Pittsburghn = 105May 2009 to Jun 2012

Osteoporosis

Trial page ClinicalTrials.govUpdated 24 Mar 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.